Although many approaches, including PD-1/PD-L1 targeting and CTLA-4 targeting, have been tested during clinical trials of CRC patients, these have failed to achieve satisfactory beneficial effects.3 Therefore, the introduction of novel immunotherapies to clinical routines may be considered a priority. The gene discussed is CTLA4; the disease is colorectal carcinoma.